Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch & Lomb IOL deal

This article was originally published in The Gray Sheet

Executive Summary

Eye care giant gains worldwide rights, excluding Japan, to Santen Pharmaceutical's hydrophobic acrylic polymers, which will be used in the development of intraocular lenses. B&L currently markets IOL products including Crystalens, the only FDA-approved accommodating IOL, Akreos and SofPort. The acquisition of Crystalens maker Eyeonics in 2008 marked B&L's entry into the premium IOL market, in which it competes with Alcon and Abbott subsidiary Advanced Medical Optics (1"The Gray Sheet" Jan. 28, 2008, p. 3)

You may also be interested in...

Bausch & Lomb Buys Eyeonics, Enters Premium IOL Market With Crystalens

Bausch & Lomb will enter the fast-growing premium intraocular lens market for the first time through its acquisition of Crystalens maker Eyeonics under a pact announced Jan. 20

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts